Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive melanoma with central nervous system (CNS) metastases (mets): Final results and exploratory biomarker analysis from the phase 2 TRICOTEL study

被引：0
作者：
Dummer, Reinhard
Levesque, Mitchell
Bellini, Elisa
Chen, Marissa
Hu, Youyou
Wong, Tiffany
Stassen, Katja
Duhard, Pauline
Yan, Yibing
Tawbi, Hussein A.
机构：
[1] Univ Hosp Zurich, Zurich, Switzerland
[2] ISS AG, Integrated Sci Serv, Biel, Switzerland
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] SOTIO Biotech, Basel, Switzerland
[6] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9550
引用
收藏
页数：1
相关论文
共 26 条
  • [21] Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis
    Blank, Christian U.
    Larkin, James
    Arance, Ana M.
    Hauschild, Axel
    Queirolo, Paola
    Del Vecchio, Michele
    Ascierto, Paolo A.
    Krajsova, Ivana
    Schachter, Jacob
    Neyns, Bart
    Garbe, Claus
    Sileni, Vanna Chiarion
    Mandala, Mario
    Gogas, Helen
    Espinosa, Enrique
    Hospers, Geke A. P.
    Miller, Wilson H., Jr.
    Robson, Susan
    Makrutzki, Martina
    Antic, Vladan
    Brown, Michael P.
    EUROPEAN JOURNAL OF CANCER, 2017, 79 : 176 - 184
  • [22] Phase 1 trial of MEK1 inhibitor E6201 plus dabrafenib in patients (pts) with BRAF V600-mutated metastatic melanoma (MM) with central nervous system (CNS) metastases (mets)
    Seetharam, Mahesh
    Dronca, Roxana
    Dudek, Arkadiusz Z.
    Nelson, Garth
    Block, Matthew
    Starling, Skylar
    Baskin, Amber
    Bradshaw, Renee
    Nelson, Courtney
    Andrews, Kylee
    Birgin, Alisha
    Watson, Cristina
    Yan, Yiyi
    Mahadevan, Daruka
    Markovic, Svetomir
    Myers, Tom
    Paradiso, Linda
    Babiker, Hani
    CANCER RESEARCH, 2024, 84 (07)
  • [23] BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).
    Kirkwood, John M.
    Long, Georgina V.
    Trefzer, Uwe
    Davies, Michael A.
    Ascierto, Paolo Antonio
    Chapman, Paul B.
    Puzanov, Igor
    Hauschild, Axel
    Robert, Caroline
    Kefford, Richard
    Goodman, Vicki L.
    Switzky, Julie C.
    Swann, R. Suzanne
    Martin, Anne-Marie
    Guckert, Mary E.
    Streit, Michael R. W.
    Schadendorf, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): Primary efficacy analysis results from the phase II PATRICIA study
    Lin, Nancy U.
    Kumthekar, Priya
    Sahebjam, Solmaz
    Ibrahim, Nuhad
    Fung, Anita
    Cheng, Anna
    Nicholas, Alan
    Wang, Bei
    Pegram, Mark
    CANCER RESEARCH, 2020, 80 (04)
  • [25] Efficacy and safety of trastuzumab emtansine (T-DM1) vs lapatinib plus capecitabine (XL) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and central nervous system (CNS) metastases: Results from a retrospective exploratory analysis of EMILIA
    Krop, I.
    Lin, N.
    Blackwell, K.
    Guardino, E.
    Huober, J.
    Lu, M.
    Miles, D.
    Samant, M.
    Welslau, M.
    Dieras, V.
    CANCER RESEARCH, 2013, 73
  • [26] Ribociclib (RIB) plus letrozole (LET) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (ER2-) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial
    Cottu, P. H.
    De Laurentiis, M.
    Marchetti, P.
    Coltelli, L.
    Califaretti, N.
    Debled, M.
    Patil, S.
    Evron, E.
    Duhoux, F. P.
    Menon-Singh, L.
    Wu, J.
    Zhou, K.
    Salvador Bofill, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 118 - 118
123